Clinical Trials Logo

Clinical Trial Summary

The PORTAL study will test a new combination of drugs (glofitamab, polatuzumab vedotin and obinutuzumab) in patients with large B-cell lymphoma (LBCL) that has come back (relapsed) or not responded to previous treatment. It will determine how safe and effective the combination of these cancer drugs is in treating LBCL before and after CAR-T cell therapy.


Clinical Trial Description

This is a phase 2, open label trial conducted in 2 parts. The overall aim is: Part 1: To determine the efficacy of Pola-Glofit as bridging treatment to CAR-T cell therapy in patients with relapsed or refractory large B cell lymphomas. Part 2: To determine the efficacy of Pola-Glofit in patients with relapsed or refractory large B cell lymphomas who have failed to achieve CMR, or progressed after CAR-T cell therapy. Treatment consists of: Part 1: Patients will receive 2 cycles of Pola-Glofit. Obinutuzumab is given 7 days before the first dose of Glofit. After 2 cycles, patients have a PET-CT scan to check the response. If the scan shows a response and the patient is still suitable for CAR-T, patients will receive planned CAR-T therapy. If the patient is not suitable to continue with CAR-T, patients can receive up to 4 more cycles of Pola-Glofit, and then 6 cycles of Glofit. Part 2: Patients will receive 6 cycles of Pola-Glofit, and then 6 cycles of Glofit. Obinutuzumab is given 7 days before the first dose of Glofit. For both Part 1 and Part 2, all cycles are 21 days. A step-up dosing regimen will be followed: - Cycle 1 Day 1: Obinutuzumab is given intravenously at a dose of 1g over 4-5 hours. - Cycle 1 Day 2: Polatuzumab is given intravenously at a dose of 1.8mg/kg over 90 minutes. - Cycle 1 Day 8: Glofitamab is given intravenously at a dose of 2.5mg over 4 hours. Patients need to stay in hospital for 24 hours. - Cycle 1 Day 15: Glofitamab is given intravenously at a dose of 10mg over 2 hours. (Patients may need to stay in hospital for 24 hours.) - From Cycle 2-6, Polatuzumab is given intravenously at a dose of 1.8mg/kg over 30 minutes on Day 1, and Glofitamab is given intravenously at a dose of 30mg over 2 hours on Day 1. - From Cycle 7-12, Glofitamab is given intravenously at a dose of 30mg over 2 hours on Day 1. Patients will be followed up until the last patient completes their 1 year post-treatment follow up visit. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06071871
Study type Interventional
Source University College, London
Contact PORTAL Trial Manager
Phone 020 7679 9860
Email ctc.portal@ucl.ac.uk
Status Not yet recruiting
Phase Phase 2
Start date April 30, 2024
Completion date July 31, 2028

See also
  Status Clinical Trial Phase
Withdrawn NCT05929716 - An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma Phase 2
Recruiting NCT05464719 - A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy Phase 2
Recruiting NCT06047080 - An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma Phase 3
Active, not recruiting NCT04566978 - 89Zr-DFO-REGN3767 in PET Scans in People With Diffuse Large B Cell Lymphoma (DLBCL) Early Phase 1
Recruiting NCT06104592 - Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL Phase 2
Recruiting NCT04889716 - CAR-T Followed by Bispecific Antibodies Phase 2
Recruiting NCT04250324 - Study of Safety and Efficacy of BZ019 in (R/R) Large B-cell Lymphoma Phase 1
Recruiting NCT05326243 - Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma Phase 1/Phase 2
Recruiting NCT05794958 - Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel Phase 1
Recruiting NCT06285422 - Study Evaluating SC262 in Subjects With r/r Non-Hodgkin's Lymphoma (VIVID) Phase 1
Recruiting NCT05404048 - PD-L1 PET-imaging During CAR T-cell Therapy Phase 2
Recruiting NCT06375733 - A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL Phase 1/Phase 2
Recruiting NCT05887167 - Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies Phase 1
Recruiting NCT05648019 - CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol Phase 2
Recruiting NCT05643742 - A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies Phase 1/Phase 2
Recruiting NCT05820841 - Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma Phase 3
Recruiting NCT05472610 - Study of Efficacy of BZ019 in Large B-cell Lymphoma Phase 2
Recruiting NCT03960840 - Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, ALL and 1L HR LBCL Phase 1/Phase 2
Recruiting NCT06356129 - Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma Phase 3
Recruiting NCT05665062 - Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies Phase 1